Azora Therapeutics Email Format
Pharmaceutical ManufacturingCalifornia, United States2-10 Employees
Azora Therapeutics is a small clinical-stage pharmaceutical company based in Playa Del Rey, California, focused on developing therapies for serious inflammatory diseases. Its work centers on novel treatments for conditions such as hidradenitis suppurativa and ulcerative colitis, with programs aimed at addressing inflammatory pathology. The company operates with a compact team and engages in early-stage therapeutic development within the broader pharmaceutical sector. In June 2026, Azora Therapeutics was acquired by Adial Pharmaceuticals. Following the acquisition, Adial's lead program is AT177, a colon-targeted aryl hydrocarbon receptor agonist designed to enable localized activation in the colon with limited systemic exposure for ulcerative colitis.